Tools
Stock profile

Beta Bionics, Inc. (BBNX)

BBNX · Latest close $14.33 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$14.33
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
3
vs previous quarter

Beta Bionics, Inc. (BBNX) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.6M sold). Latest close $14.33 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-2.6M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Insider trading · 5% holders · Politician trading · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Deerfield Management · RTW Investments · Perceptive Advisors — 3 tracked funds hold BBNX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 20 sales ($2.6M). Insider trading

Often held alongside

Celcuity Inc. (CELC) · COGENT BIOSCIENCES INC (COGT) · TANGO THERAPEUTICS INC (TNGX) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Deerfield Management0.22%1,324,000HELD Q3 filed Nov 16
RTW Investments0.20%1,500,000TRIMMED (-25.0%) Q3 filed Nov 16
Perceptive Advisors0.20%832,944TRIMMED (-1.2%) Q3 filed Nov 16
First Eagle Investment Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -11.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

31.997.932025-01-302026-11-18

Closing prices (unadjusted for dividends), last 2 years — 454 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding137 of 8,857 filers
Long-only filers among them134
Change vs 2026 Q1+10 net · 136 entered · 126 exited
Shares reported, all filers47,972,785
Reported value, all filers$753.7M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$100.3M
Net income · FY2025$-73.2M
Total assets · FY2025$328.7M
Shares outstanding54,367,067
Market cap (at latest close)$779.1M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 26, 2026.

Short interest

Shares short · Oct 15, 20266,917,021
Share of shares outstanding12.72%
Days to cover7.38

Shares short at recent settlements — Jul 31, 2026: 7.6M · Aug 14, 2026: 7.5M · Aug 31, 2026: 9.4M · Sep 15, 2026: 10.6M · Sep 30, 2026: 6.0M · Oct 15, 2026: 6.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 26, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 20 sales by 6 insiders ($2.6M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 16, 2026Hopman MarkChief Commercial OfficerSell775$16.22$12.6KSEC filing
Nov 11, 2026Feider StephenChief Financial OfficerSell8,874$17.21$152.7KSEC filing
Nov 9, 2026Feider StephenChief Financial OfficerSell744$17.00$12.6KSEC filing
Nov 5, 2026Feider StephenChief Financial OfficerSell382$17.04$6.5KSEC filing
Nov 2, 2026Hopman MarkChief Commercial OfficerSell370$16.90$6.3KSEC filing
Oct 27, 2026Mensinger MikeChief Product OfficerSell2,650$22.00$58.3KSEC filing
Oct 26, 2026Hopman MarkChief Commercial OfficerSell821$20.00$16.4KSEC filing
Oct 14, 2026Hopman MarkChief Commercial OfficerSell775$17.35$13.4KSEC filing
Oct 1, 2026Hopman MarkChief Commercial OfficerSell370$18.96$7.0KSEC filing
Sep 22, 2026Jones ChristySell6,430$23.00$147.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 13, 2026Farallon Capital Management, L.L.C.SC 13G/A595,0001.3%Jun 30, 2026SEC filing
Jul 24, 2026Divisadero Street Capital Management, LPSC 13G3,072,9856.9%Jul 17, 2026SEC filing
May 15, 2026Eventide Asset Management, LLCSC 13G/A5,945,48813.4%Mar 31, 2026SEC filing
May 15, 2026RTW Investments, LPSC 13G/A2,000,0004.5%Mar 31, 2026SEC filing
May 12, 2026Zone Healthcare Holdings, LLCSC 13G/A2,560,2205.8%Mar 31, 2026SEC filing
May 8, 2026Soleus Private Equity Fund II, L.P.SC 13G/A1,703,9613.8%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 23, 2026Point72 Asset Management, L.P.SC 13G2,290,0235.2%Feb 18, 2026SEC filing
Feb 17, 2026RTW Investments, LPSC 13G/A2,500,0005.7%Dec 31, 2025SEC filing
Feb 12, 2026Soleus BB SPV, LLCSC 13G/A00.0%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Government relations

Lobbying: 8 Lobbying Disclosure Act filings named this company as client, 2021–2022; most common issues: Health Issues (8).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Chart Signals

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· Excess Accruals (Sloan) — Accruals ratio: 42.8% · Net income: $-73.2M · Operating cash flow: $-50.9M · Investing cash flow: $-162.8M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold BBNX — ranked by lift, the co-holding pattern described in Methodology: Celcuity Inc. (CELC) · COGENT BIOSCIENCES INC (COGT) · TANGO THERAPEUTICS INC (TNGX).

Recent 8-K filings

FiledItemsSource
Oct 27, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Sep 17, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Sep 15, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Celcuity Inc. (CELC) · Track Record: how the signals scored · Practice timing on BBNX

One email a week: the week’s new filings and research. Subscribe free

← BBIO  ·  BBOT →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.